Pfizer Built an AI Advantage in Drug Development Speed
Pfizer identifies promising drug candidates in 30 days and freed 16,000 researcher hours annually through AI deployment across discovery and manufacturing.
Pfizer is applying AI across drug discovery, manufacturing, and research workflows, with measurable gains in speed, output, and cost.
The company reports it can identify promising drug candidates in 30 days by screening millions of compounds using AI. In parallel, it has increased manufacturing throughput by 20% using anomaly detection systems and freed 16,000 researcher hours annually through natural language search tools, extending these gains beyond discovery into operations and research productivity.
These operational improvements tie into a broader cost program. Pfizer reported $1.2 billion in digital enablement savings in its Q1 2025 earnings release, and expects to deliver most of its total $7.2 billion savings target by the end of 2026.
AI Compresses Early Discovery
Drug discovery has historically required months or years of laboratory work to identify viable compounds. Pfizer’s AI platform reportedly shifts that step by screening millions of candidates in 30 days, compressing the earliest phase of the pipeline.
While this reduces time at the front end, the rest of the development cycle remains unchanged in duration. Preclinical testing, clinical trials, and regulatory approval still extend total timelines to 8 to 15 years, keeping overall timelines long even as early-stage discovery accelerates.
That earlier acceleration feeds into production. Pfizer applies AI models in manufacturing to detect anomalies and recommend corrections in real time, translating upstream speed into downstream output gains. In certain processes, this has increased throughput by 20%. In COVID-19 vaccine production, the same approach added about 20,000 doses per batch.
A similar shift appears in research workflows. Scientists often spend days searching across literature and internal datasets, which slows iteration. Pfizer’s natural language search system reduces that time and frees approximately 16,000 hours annually, allowing researchers to focus on hypothesis testing and analysis (AWS case study).
A Decade of AI Investment
These capabilities build on a longer timeline of AI adoption. Pfizer began using AI in pharmacovigilance in 2014, expanded into molecular modeling through a 2016 partnership with XtalPi, and added machine learning for small molecule design through PostEra in 2020. Together, these systems contributed to the development of Paxlovid during 2020–2021.
The company has continued to expand this ecosystem. In 2025, Pfizer announced collaborations with Data4Cure and additional work with XtalPi, reinforcing its external partnerships. It also appointed Berta Rodriguez-Hervas as Chief AI and Analytics Officer in August 2024.
Scaling Data Infrastructure and Compute
Internally, Pfizer is scaling infrastructure to support these efforts. It is building a Scientific Data Cloud with AWS that aggregates data from hundreds of laboratory instruments, creating a centralized foundation for AI models. This platform enables 75% faster data generation for drug submissions. The company also plans to expand its GPU infrastructure to more than 1,200 units over the next two years.
The Paxlovid program shows how these elements combine in practice. Pfizer used AI and supercomputing to develop nirmatrelvir, reducing computational time by 80% to 90% compared to prior methods. At the same time, supply chain cycle time for a critical manufacturing step fell by 67%, increasing batch output.
This approach is developing alongside broader industry adoption. Merck is investing in AI across drug development while maintaining human oversight. AstraZeneca is working with BenevolentAI on discovery, and Johnson and Johnson is running more than 100 AI initiatives across clinical trials, recruitment, and research.
Market projections reflect that expansion. Estimates place the AI in pharmaceutical market at $1.94 billion in 2025, growing to $16.49 billion by 2034.
Pfizer’s work focuses on reducing time in early discovery, increasing manufacturing output, and shifting researcher effort toward higher-value tasks, while the overall drug development timeline remains largely unchanged.